Economic Burden Analysis of Parkinson’s Disease Patients in China

Table 3

Univariate analyses of contributions of various factors to the cost of PD ($, 2016 values).

Characteristics		Mean	Median			Mean rank
Sex
Male	72	2626.44	1141.15	587.03	3461.17	8.05
Female	44	4206.96	1373.20	758.55	4491.21	9.04
Age
≤60 years	27	4193.49	1583.65	747.62	6880.35	9.55
61–70 years	48	2280.62	890.48	631.19	2413.64	7.73
≥71 years	41	3695.51	6295.98	513.73	4054.51	8.50
Duration of disease
1–5 years	71	2075.92	796.02	536.57	1583.65	6.98
6–10 years	33	4600.23	2774.03	683.60	6006.25	9.75
>10 years	12	6251.00	6209.40	1908.07	9664.85	13.31
Delayed diagnosis
≤2 years	91	3152.85	978.64	627.20	2921.30	8.06
≤5 years	18	2877.63	1208.53	584.61	5292.34	8.63
>5 years	7	5071.96	2774.03	1822.18	9408.40	12.57
HY stage
HY I	32	1055.23	749.72	425.56	1445.52	5.93
HY II	37	1352.50	850.04	348.86	1480.91	6.72
HY III	29	6917.09	3858.03	936.91	9293.66	11.14
HY IV	9	6264.64	5379.19	1421.05	10206.00	12.78
HY V	9	3713.63	4282.27	1541.82	5441.76	11.19
Past history
No	86	2760.31	999.28	602.26	3902.76	8.11
Hypertension	8	11643.62	5324.07	1012.57	18502.35	11.56
Diabetes	4	1099.16	659.39	278.21	2359.87	5.26
Angiocardiopathy	11	1778.42	1316.31	693.57	2723.36	8.51
CI	7	2816.39	2687.50	958.62	4557.04	10.35
Surgical therapy
No	113	2468.63	1252.39	635.19	3741.53	8.21
Yes	3	31751.49	2578.24	21196.31		16.56
Antiparkinsonian drug levodopa costs
≤455.625	41	2063.41	791.36	695.40	2023.34	7.51
≤675	40	2675.48	1004.27	341.80	3587.03	7.73
≤911.25	11	8073.97	4282.27	1019.93	8535.38	11.17
>911.25	21	3907.39	2426.61	685.98	5657.59	9.89
Dopamine agonists costs
0	38	1672.29	427.42	277.88	2276.65	5.84
≤2365.2	10	8196.79	6410.02	484.27	13114.41	10.66
≤3547.8	55	3350.52	1252.39	791.36	4122.04	9.21
>3547.8	13	3416.75	1469.23	1469.23	4403.86	10.93

test of two independent samples. test of multigroup independent samples.